SELLAS Life Sciences Group, Inc. (SLS)
NASDAQ: SLS · Real-Time Price · USD
1.270
-0.040 (-3.05%)
At close: Feb 21, 2025, 4:00 PM
1.260
-0.010 (-0.78%)
After-hours: Feb 21, 2025, 7:59 PM EST
SLS Employees
SELLAS Life Sciences Group had 16 employees as of December 31, 2023. The number of employees decreased by 1 or -5.88% compared to the previous year.
Employees
16
Change (1Y)
-1
Growth (1Y)
-5.88%
Revenue / Employee
n/a
Profits / Employee
-$2,017,500
Market Cap
89.39M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
SLS News
- 3 days ago - SELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCL - GlobeNewsWire
- 25 days ago - SELLAS Life Sciences Group Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - GlobeNewsWire
- 4 weeks ago - SELLAS Life Sciences Announces Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia - GlobeNewsWire
- 6 weeks ago - SELLAS Announces Key Business Objectives for 2025 - GlobeNewsWire
- 2 months ago - SELLAS Life Sciences Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia - GlobeNewsWire
- 2 months ago - SELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 in r/r AML - GlobeNewsWire
- 3 months ago - SELLAS Announces Positive Data from Preclinical Studies Indicating ASXL1 Mutations as Predictor of Response to SLS009 in Solid Cancers - GlobeNewsWire
- 3 months ago - SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire